Mantle Cell Lymphoma: Rituximab + Lenalidomide Promising as First-Line Therapy

According to a study, he combination of rituximab and lenalidomide shows evidence of effectively managing mantle cell lymphoma (MCL), generally considered incurable, while avoiding the side effects associated with more intensive treatments.